Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations
Some 30% of the physicians in the U.S. sold their practices, which in turn commensurately reduced the number of physicians who are willing and able to be called on by sales reps.
Valeant's missteps derailed Addyi; Biogen reportedly considers selling its hemophilia treatment portfolio; Roche's PD-LI inhibitor granted Priority Review
After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.
Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza
Symptom-driven care is falling out of favor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.
GlaxoSmithKline's Advair brought in $4.8 billion in U.S. sales in 2015, edging out Boehringer Ingelheim's Spiriva Handihaler ($3.4 billion) and AstraZeneca's Symbicort ($2.6 billion).
There are big changes underway in the doctor-patient relationship, a study suggests, and it's a new reality to which biopharma must adjust.
Entresto's sales are still lower than expected; GSK CEO Witty to retire in 2017; tech assistants sometimes fail to account for women's health needs
IBS drug Xifaxan missed the company's sales projection for the fourth quarter of 2015 by $180 million.
- When it comes to professional ads, print makes its comeback
- Amgen takes issue with yet-to-be published multiple-myeloma drug report
- How Watson for Oncology is advancing cancer care
- Creative partners should push pharma clients to tell better stories
- Retaining talent: How pharma can compete with Google